Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis

OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot. DESIGNProspective,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical care medicine 2002-05, Vol.30 (5), p.974-980
Hauptverfasser: Goldfarb, Roy D, Marton, Anita, Szabó, Éva, Virág, László, Salzman, Andrew L, Glock, Dana, Akhter, Imran, McCarthy, Robert, Parrillo, Joseph E, Szabó, Csaba
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 980
container_issue 5
container_start_page 974
container_title Critical care medicine
container_volume 30
creator Goldfarb, Roy D
Marton, Anita
Szabó, Éva
Virág, László
Salzman, Andrew L
Glock, Dana
Akhter, Imran
McCarthy, Robert
Parrillo, Joseph E
Szabó, Csaba
description OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot. DESIGNProspective, random animal study. SETTINGResearch laboratory at Rush Presbyterian St. Luke’s Medical Center. SUBJECTSTwenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diameter, an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressures and collect samples. INTERVENTIONSBy using a randomized study design, we administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 hr, 2 mg·kg·hr for 96 hrs) or vehicle to pigs immediately before intraperitoneal implantation of Escherichia coli 0111.B4 (2.3 ± 0.1 × 10 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia. MEASUREMENTS AND MAIN RESULTSIn vehicle-treated pigs, 12% survival was recorded at 24 hrs, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 hrs, respectively (p < .05). PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances. In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-α. PJ34 treatment significantly attenuated this cytokine response. The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochemical detection of nitrotyrosine and poly(ADP-ribose), respectively. Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals. CONCLUSIONSTreatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.
doi_str_mv 10.1097/00003246-200205000-00004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71677540</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71677540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4524-37e0b43f48833d53358716af04872ecd6c65a66b97488048ef45204a3cf264f43</originalsourceid><addsrcrecordid>eNp1ksGOFCEQhonRuLOrr2C4aDSxlW6g6T5uNrqabKIHPROaLtIo07QUM5u5-Qw-io_kk0g7o3uSC1Tx_X8l_BBCa_aqZr16zcrijWirhrGGyVJVa0vcI5ta8lI0Pb9PNoz1rOKi52fkHPELY7WQij8kZ3XRtapnG_LjY4oZbPZ7oOBcOdHoqKFz3EN4SZdyOWfq58kPPse0Xi4xHJ6bEeaIfgYqf33_WY1-mSIuk8lQJT9EhBcUD3OeIBuEoi-WS0x2FWzjCGE1QthDAjoYmyF5E0pjQY-PyANnAsLj035BPr998-nqXXXz4fr91eVNZYVsRMUVsEFwJ7qO81FyLjtVt8Yx0akG7NjaVpq2HXpViNIEV2RMGG5d0won-AV5dvRdUvy2A8x669FCCGaGuENd3JSSghWwO4I2RcQETi_Jb0066JrpNQ_9Nw_9L48_rXXGk9OM3bCF8U54CqAAT0-AQWuCS2a2Hu84USsmeVc4ceRuYyivhV_D7haSnsCEPOn__Qf-G4japAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71677540</pqid></control><display><type>article</type><title>Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>Goldfarb, Roy D ; Marton, Anita ; Szabó, Éva ; Virág, László ; Salzman, Andrew L ; Glock, Dana ; Akhter, Imran ; McCarthy, Robert ; Parrillo, Joseph E ; Szabó, Csaba</creator><creatorcontrib>Goldfarb, Roy D ; Marton, Anita ; Szabó, Éva ; Virág, László ; Salzman, Andrew L ; Glock, Dana ; Akhter, Imran ; McCarthy, Robert ; Parrillo, Joseph E ; Szabó, Csaba</creatorcontrib><description>OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot. DESIGNProspective, random animal study. SETTINGResearch laboratory at Rush Presbyterian St. Luke’s Medical Center. SUBJECTSTwenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diameter, an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressures and collect samples. INTERVENTIONSBy using a randomized study design, we administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 hr, 2 mg·kg·hr for 96 hrs) or vehicle to pigs immediately before intraperitoneal implantation of Escherichia coli 0111.B4 (2.3 ± 0.1 × 10 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia. MEASUREMENTS AND MAIN RESULTSIn vehicle-treated pigs, 12% survival was recorded at 24 hrs, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 hrs, respectively (p &lt; .05). PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances. In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-α. PJ34 treatment significantly attenuated this cytokine response. The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochemical detection of nitrotyrosine and poly(ADP-ribose), respectively. Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals. CONCLUSIONSTreatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/00003246-200205000-00004</identifier><identifier>PMID: 12006790</identifier><identifier>CODEN: CCMDC7</identifier><language>eng</language><publisher>Hagerstown, MD: by the Society of Critical Care Medicine and Lippincott Williams &amp; Wilkins</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Bacterial Infections - drug therapy ; Biological and medical sciences ; Disease Models, Animal ; Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care ; Emergency and intensive care: infection, septic shock ; Enzyme Inhibitors - therapeutic use ; Escherichia coli Infections - drug therapy ; Hemodynamics - drug effects ; Intensive care medicine ; Medical sciences ; Peritonitis - drug therapy ; Phenanthrenes - therapeutic use ; Poly(ADP-ribose) Polymerase Inhibitors ; Prospective Studies ; Random Allocation ; Swine ; Tumor Necrosis Factor-alpha - analysis</subject><ispartof>Critical care medicine, 2002-05, Vol.30 (5), p.974-980</ispartof><rights>2002 by the Society of Critical Care Medicine and Lippincott Williams &amp; Wilkins</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4524-37e0b43f48833d53358716af04872ecd6c65a66b97488048ef45204a3cf264f43</citedby><cites>FETCH-LOGICAL-c4524-37e0b43f48833d53358716af04872ecd6c65a66b97488048ef45204a3cf264f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14170538$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12006790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldfarb, Roy D</creatorcontrib><creatorcontrib>Marton, Anita</creatorcontrib><creatorcontrib>Szabó, Éva</creatorcontrib><creatorcontrib>Virág, László</creatorcontrib><creatorcontrib>Salzman, Andrew L</creatorcontrib><creatorcontrib>Glock, Dana</creatorcontrib><creatorcontrib>Akhter, Imran</creatorcontrib><creatorcontrib>McCarthy, Robert</creatorcontrib><creatorcontrib>Parrillo, Joseph E</creatorcontrib><creatorcontrib>Szabó, Csaba</creatorcontrib><title>Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot. DESIGNProspective, random animal study. SETTINGResearch laboratory at Rush Presbyterian St. Luke’s Medical Center. SUBJECTSTwenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diameter, an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressures and collect samples. INTERVENTIONSBy using a randomized study design, we administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 hr, 2 mg·kg·hr for 96 hrs) or vehicle to pigs immediately before intraperitoneal implantation of Escherichia coli 0111.B4 (2.3 ± 0.1 × 10 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia. MEASUREMENTS AND MAIN RESULTSIn vehicle-treated pigs, 12% survival was recorded at 24 hrs, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 hrs, respectively (p &lt; .05). PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances. In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-α. PJ34 treatment significantly attenuated this cytokine response. The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochemical detection of nitrotyrosine and poly(ADP-ribose), respectively. Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals. CONCLUSIONSTreatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Bacterial Infections - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Disease Models, Animal</subject><subject>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</subject><subject>Emergency and intensive care: infection, septic shock</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Escherichia coli Infections - drug therapy</subject><subject>Hemodynamics - drug effects</subject><subject>Intensive care medicine</subject><subject>Medical sciences</subject><subject>Peritonitis - drug therapy</subject><subject>Phenanthrenes - therapeutic use</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors</subject><subject>Prospective Studies</subject><subject>Random Allocation</subject><subject>Swine</subject><subject>Tumor Necrosis Factor-alpha - analysis</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ksGOFCEQhonRuLOrr2C4aDSxlW6g6T5uNrqabKIHPROaLtIo07QUM5u5-Qw-io_kk0g7o3uSC1Tx_X8l_BBCa_aqZr16zcrijWirhrGGyVJVa0vcI5ta8lI0Pb9PNoz1rOKi52fkHPELY7WQij8kZ3XRtapnG_LjY4oZbPZ7oOBcOdHoqKFz3EN4SZdyOWfq58kPPse0Xi4xHJ6bEeaIfgYqf33_WY1-mSIuk8lQJT9EhBcUD3OeIBuEoi-WS0x2FWzjCGE1QthDAjoYmyF5E0pjQY-PyANnAsLj035BPr998-nqXXXz4fr91eVNZYVsRMUVsEFwJ7qO81FyLjtVt8Yx0akG7NjaVpq2HXpViNIEV2RMGG5d0won-AV5dvRdUvy2A8x669FCCGaGuENd3JSSghWwO4I2RcQETi_Jb0066JrpNQ_9Nw_9L48_rXXGk9OM3bCF8U54CqAAT0-AQWuCS2a2Hu84USsmeVc4ceRuYyivhV_D7haSnsCEPOn__Qf-G4japAA</recordid><startdate>200205</startdate><enddate>200205</enddate><creator>Goldfarb, Roy D</creator><creator>Marton, Anita</creator><creator>Szabó, Éva</creator><creator>Virág, László</creator><creator>Salzman, Andrew L</creator><creator>Glock, Dana</creator><creator>Akhter, Imran</creator><creator>McCarthy, Robert</creator><creator>Parrillo, Joseph E</creator><creator>Szabó, Csaba</creator><general>by the Society of Critical Care Medicine and Lippincott Williams &amp; Wilkins</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200205</creationdate><title>Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</title><author>Goldfarb, Roy D ; Marton, Anita ; Szabó, Éva ; Virág, László ; Salzman, Andrew L ; Glock, Dana ; Akhter, Imran ; McCarthy, Robert ; Parrillo, Joseph E ; Szabó, Csaba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4524-37e0b43f48833d53358716af04872ecd6c65a66b97488048ef45204a3cf264f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Bacterial Infections - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Disease Models, Animal</topic><topic>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</topic><topic>Emergency and intensive care: infection, septic shock</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Escherichia coli Infections - drug therapy</topic><topic>Hemodynamics - drug effects</topic><topic>Intensive care medicine</topic><topic>Medical sciences</topic><topic>Peritonitis - drug therapy</topic><topic>Phenanthrenes - therapeutic use</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors</topic><topic>Prospective Studies</topic><topic>Random Allocation</topic><topic>Swine</topic><topic>Tumor Necrosis Factor-alpha - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldfarb, Roy D</creatorcontrib><creatorcontrib>Marton, Anita</creatorcontrib><creatorcontrib>Szabó, Éva</creatorcontrib><creatorcontrib>Virág, László</creatorcontrib><creatorcontrib>Salzman, Andrew L</creatorcontrib><creatorcontrib>Glock, Dana</creatorcontrib><creatorcontrib>Akhter, Imran</creatorcontrib><creatorcontrib>McCarthy, Robert</creatorcontrib><creatorcontrib>Parrillo, Joseph E</creatorcontrib><creatorcontrib>Szabó, Csaba</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldfarb, Roy D</au><au>Marton, Anita</au><au>Szabó, Éva</au><au>Virág, László</au><au>Salzman, Andrew L</au><au>Glock, Dana</au><au>Akhter, Imran</au><au>McCarthy, Robert</au><au>Parrillo, Joseph E</au><au>Szabó, Csaba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>2002-05</date><risdate>2002</risdate><volume>30</volume><issue>5</issue><spage>974</spage><epage>980</epage><pages>974-980</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><coden>CCMDC7</coden><abstract>OBJECTIVETo determine whether activation of the nuclear enzyme poly(adenosine 5′-diphosphate [ADP]-ribose) synthetase (PARS) contributes to mortality rate, myocardial dysfunction, and cardiovascular collapse in a porcine model of sepsis induced by implantation of an infected clot. DESIGNProspective, random animal study. SETTINGResearch laboratory at Rush Presbyterian St. Luke’s Medical Center. SUBJECTSTwenty pigs were chronically instrumented with intracardiac transducers to measure left ventricular pressure, sonomicrometer crystals in the left ventricle to measure short axis diameter, an ultrasonic flow meter to measure cardiac output, and catheters in the pulmonary artery and aorta to measure blood pressures and collect samples. INTERVENTIONSBy using a randomized study design, we administered either the novel potent PARS inhibitor PJ34 (10 mg/kg for 1 hr, 2 mg·kg·hr for 96 hrs) or vehicle to pigs immediately before intraperitoneal implantation of Escherichia coli 0111.B4 (2.3 ± 0.1 × 10 colony-forming units/kg)-laden fibrin clots to produce peritonitis and bacteremia. MEASUREMENTS AND MAIN RESULTSIn vehicle-treated pigs, 12% survival was recorded at 24 hrs, whereas 83% and 66% survival was recorded in the PJ34-treated animals at 24 and 96 hrs, respectively (p &lt; .05). PJ34 treatment attenuated bacteremia-induced increases in systemic and pulmonary vascular resistances. In controls, peritonitis induced rapid increase in plasma tumor necrosis factor-α. PJ34 treatment significantly attenuated this cytokine response. The formation of peroxynitrite and the activation of PARS were confirmed in hearts and lungs of the septic pigs by the immunohistochemical detection of nitrotyrosine and poly(ADP-ribose), respectively. Inhibition of PARS with PJ34 abolished poly(ADP-ribose) formation in septic animals. CONCLUSIONSTreatment with a potent PARS inhibitor improved survival and cardiovascular status and attenuated an important mediator component of the inflammatory response in a lethal porcine model of sepsis.</abstract><cop>Hagerstown, MD</cop><pub>by the Society of Critical Care Medicine and Lippincott Williams &amp; Wilkins</pub><pmid>12006790</pmid><doi>10.1097/00003246-200205000-00004</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-3493
ispartof Critical care medicine, 2002-05, Vol.30 (5), p.974-980
issn 0090-3493
1530-0293
language eng
recordid cdi_proquest_miscellaneous_71677540
source Journals@Ovid Ovid Autoload; MEDLINE
subjects Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Animals
Bacterial Infections - drug therapy
Biological and medical sciences
Disease Models, Animal
Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care
Emergency and intensive care: infection, septic shock
Enzyme Inhibitors - therapeutic use
Escherichia coli Infections - drug therapy
Hemodynamics - drug effects
Intensive care medicine
Medical sciences
Peritonitis - drug therapy
Phenanthrenes - therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors
Prospective Studies
Random Allocation
Swine
Tumor Necrosis Factor-alpha - analysis
title Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T10%3A46%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20effect%20of%20a%20novel,%20potent%20inhibitor%20of%20poly(adenosine%205%E2%80%B2-diphosphate-ribose)%20synthetase%20in%20a%20porcine%20model%20of%20severe%20bacterial%20sepsis&rft.jtitle=Critical%20care%20medicine&rft.au=Goldfarb,%20Roy%20D&rft.date=2002-05&rft.volume=30&rft.issue=5&rft.spage=974&rft.epage=980&rft.pages=974-980&rft.issn=0090-3493&rft.eissn=1530-0293&rft.coden=CCMDC7&rft_id=info:doi/10.1097/00003246-200205000-00004&rft_dat=%3Cproquest_cross%3E71677540%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71677540&rft_id=info:pmid/12006790&rfr_iscdi=true